We do rocket science transactions

Capital market transactions include, amongst other things:

• CHF 811 million IPO of the Baloise Swiss Property Fund on the SIX Swiss Exchange
• Initial public offering and capital increase of RealUnit Schweiz AG on the BX Swiss
• Initial public offering of Edisun Power on the SIX Swiss Exchange
• Capital increase of 3S Swiss Solar Systems and public takeover/merger with Meyer Burger
• Advising numerous banks and SPVs on the issuance of structured products (including actively managed certificates, AMCs) and exchange-traded products (ETPs)
• Listings of numerous exchange-traded funds (ETFs) on the SIX Swiss Exchange
• Execution of several securitisation transactions
• Large-scale and cross-border M&A transactions
• Advising on new segments for the BX BerneXchange
• Support for VSG Vange Software Group AG (a Chinese software company) in its IPO on the Frankfurt Stock Exchange (Entry Standard)
• Holdings structure / public takeover bid by BKW AG regarding BKW FMB Energie AG
• Advising several companies on defensive battles (references available on request)
• Advising the entrepreneur on succession planning and the sale of Schleuniger Holding AG, a manufacturer of cable processing machinery, to the Metall Zug Group
• Advising a private equity firm on the acquisition of a capital increase in a pharmaceutical company
• Advising Galenica AG, a pharmaceutical trading company listed on the SIX Swiss Exchange, on the acquisition of Aspreva Pharmaceuticals, a Canadian company listed on NASDAQ, including the financing (transaction value CHF 1.1 billion)
• Capital increase of Von Roll Holding
• Advising several major banks and listed companies on financing, including the issuance of legal opinions
• Advising foreign banks on clearing and settlement agreements, etc.
• Advising several issuers in connection with insider policies, blocking periods, disclosure obligations, management transactions, ad hoc reporting requirements and regular reporting obligations
• Advising and, in individual cases, representing clients in sanction proceedings
• Advising several issuers on corporate governance, corporate governance reports – in particular, remuneration reports – as well as the review of excerpts from annual reports
• Advising several issuers on dividend distributions exempt from withholding tax, as well as par value reductions and share buy-back programmes followed by capital reductions
• Advising institutional investors and investor groups on major transactions (merger of Novartis with Alcon following the acquisition of a majority stake from Nestlé; Actelion; sale of Synthes, etc.)